Gapping up
In reaction to earnings/guidance:
- FUBO +33.9%, LPRO +10%, ONEM +9.4%, BRKS +8.3%, FICO +6.1%, KRNT +5.6%, DOX +5.4%, LYFT +5.4%, HUYA +4.6%, SANM +4.4%, TME +4.3%, TDOC +4.3%, ADPT +4.1% (also to collaborate with GSK on clonoSEQ Assay), ASH +4%, DOYU +4%, RPRX +3.4%, ALC +3.1%, MMSI +1.8%, PRSP +1.7%, PRPL +1.3%
Other news:
- FPRX +332.6% (announces top-line results from Phase 2 FIGHT trial)
- SURF +10% (announces FDA fast track designation granted by FDA for SRF388 to treat liver cancer)
- IVA +6.6% (receives positive FDA feedback to advance its lead drug candidate)
- TLSA +6% (to collaborate with Parexel Biotech to conduct phase 1b/2 clinical trial)
- BDX +4% (announces Health Canada authorization of SARS-CoV-2 antigen test)
- GME +3.6% (will redeem $125 mln of its 6.75% Senior Notes due 2021 on December 11, 2020)
- AGTC +2.7% (reports additional positive data from its phase 1/2 clinical trial in patients with x-linked retinitis pigmentosa)
- MESO +2.5% (reports second interim analysis of clinical outcomes after 135 patients results in recommendation to continue remestemcel-L Phase 3 trial in COVID-19 ARDS) PACB +2.2% (prices offering of 7,400,460 shares of common stock at $14.25 per share)
- MYE +1.8% (acquires Elkhart Plastics)
- BA +1.7% (awarded $9.8 bln Air Force contract)
- AMD +1.7% (Advanced Micro and IBM sign multi-year agreement to jointly develop AI for both companies)
- MRNA +1.4% (announces clinical updates on personalized cancer vaccine program)
- XRX +1.2% (Carl Icahn discloses slightly increased active stake)
Analyst comments:
- MYO +15.6% (upgraded to Buy from Neutral at ROTH Capital)
- ABEO +8.7% (upgraded to Overweight from Neutral at Cantor Fitzgerald)
- DOX +5.4% (upgraded to Overweight from Neutral at JP Morgan)
- TPR +4% (upgraded to Outperform from Market Perform at Cowen)
- CRWD +3.4% (upgraded to Outperform from Neutral at Robert W. Baird)
- CNHI +3% (upgraded to Buy from Underperform at BofA Securities)
- AZN +2.2% (upgraded to Hold from Reduce at HSBC Securities)
- YELP +1.9% (upgraded to Outperform from In-line at Evercore ISI)
- HWM +1.7% (upgraded to Outperform from Market Perform at Cowen)
- DHI +1.2% (upgraded to Positive from Neutral at Susquehanna)